Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML | OncLive

Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

January 9, 2015

Bayard L. Powell, MD, Section Chief of Hematology and Oncology and Director of Leukemia Services at

Bayard L. Powell, MD, Section Chief of Hematology and Oncology and Director of Leukemia Services at

Wake Forest University Baptist Medical Center, discusses using the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).

I

look

Powell.

The results of the recent phase study promising. The combination has been effective, with 54% of patients showing a response and no increased toxicity occurring from the addition of CPI-613. The combination was particularly beneficial for patients over 60 and patients with poor risk cytogenetics, says


x